Parexel debuts its Patient Innovation Center aiming for improved biopharma development

Patients in a hospital waiting room
Parexel’s patient-centric approach and new innovation center target all areas of biopharma development from clinical trial design, recruitment, execution and market access. (Getty/SuwanPhoto)

Global CRO Parexel debuted its Patient Innovation Center that is designed to boost efficiency and success across the board for biopharmaceutical development.

Parexel’s patient-centric approach and new innovation center target all areas of biopharma development from clinical trial design, recruitment, execution and market access, the company said. Parexel’s push is supported by a recent report it commissioned from The Economist Intelligence Unit that said patient-centric trials resulted in recruiting participant patients in half the time, and that drugs developed using such an approach were 19% more likely to be launched. Despite this, the report said, a patient-centric approach was used in only 5.2% of phase 2 and 3 trials across the industry.

“While the evidence is clear that patient-centric approaches can improve the development process, many sponsors remain in need of a road map to effectively apply these strategies over time,” Sy Pretorius, M.D., a senior VP at Parexel, said in a statement. “Through the Patient Innovation Center, we aim to bring the full breadth of our services, expertise and innovation to clients to help more-effectively implement these approaches, reducing the barriers and optimizing patient involvement throughout the drug development and commercialization journey.”

INDUSTRY RESEARCH

Veeva 2019 Unified Clinical Operations Survey

Share your thoughts in this quick survey. The first 50 qualified respondents will receive a $5 Amazon gift card, and, in appreciation for your time, all qualified survey respondents will be entered in a drawing to win a $50 Amazon gift card.

A little over a year ago, Parexel merged into Pamplona Capital Management in a $5 billion deal that saw the CRO go private. In March, company co-founder Josef von Rickenbach, who was the chairman and chief executive, retired after a 35-year tenure. Jamie Macdonald, who previously led INC Research, was tapped as von Rickenbach’s replacement.